검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antihistamines |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ANTIBODY |
Overview Target | Hairy Cell Leukemia |
Overview Indication | Hairy Cell Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting TH2 pathways (dupilumab, nemolizumab), JAK inhibitors, κ-opioid receptor |
MoA Biomarker | biomarker sampling and careful causal assessment are important in similar cases |
PK/PD Species | Beagle dog, Dog, Rat |
PK/PD Animal (cat.) | Rat, Dog, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Beagle dog, Dog, Rat |
Toxicology Animal (cat.) | Rat, Dog, In vitro |
Toxicology Major finding | Anterior ST-Segment Elevation Myocardial Infarction Shortly After Cefaclor Exposure: A Case Report Highlighting Kounis Syndrome as a Differential Diagnosis.. BACKGROUND Kounis syndrome is an acute coronary syndrome associated with allergic or hypersensitivity reactions, but establishment of causality is difficult when objective allergy-related tests are unavailable during emergency treatment. This… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antihistamines |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ANTIBODY |
Overview Target | Hairy Cell Leukemia |
Overview Indication | Hairy Cell Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting TH2 pathways (dupilumab, nemolizumab), JAK inhibitors, κ-opioid receptor |
MoA Biomarker | biomarker sampling and careful causal assessment are important in similar cases |
PK/PD Species | Beagle dog, Dog, Rat |
PK/PD Animal (cat.) | Rat, Dog, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Beagle dog, Dog, Rat |
Toxicology Animal (cat.) | Rat, Dog, In vitro |
Toxicology Major finding | Anterior ST-Segment Elevation Myocardial Infarction Shortly After Cefaclor Exposure: A Case Report Highlighting Kounis Syndrome as a Differential Diagnosis.. BACKGROUND Kounis syndrome is an acute coronary syndrome associated with allergic or hypersensitivity reactions, but establishment of causality is difficult when objective allergy-related tests are unavailable during emergency treatment. This… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical PFS | 4.7 |
Clinical OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교